Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
7(50%)
Results Posted
0%(0 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_1
3
21%
Ph early_phase_1
1
7%
Ph phase_2
8
57%
Ph phase_3
1
7%

Phase Distribution

4

Early Stage

8

Mid Stage

1

Late Stage

Phase Distribution13 total trials
Early Phase 1First-in-human
1(7.7%)
Phase 1Safety & dosage
3(23.1%)
Phase 2Efficacy & side effects
8(61.5%)
Phase 3Large-scale testing
1(7.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

7

trials recruiting

Total Trials

14

all time

Status Distribution
Active(7)
Completed(3)
Terminated(2)
Other(2)

Detailed Status

Recruiting6
Completed3
unknown2
Terminated1
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
7
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (7.7%)
Phase 13 (23.1%)
Phase 28 (61.5%)
Phase 31 (7.7%)

Trials by Status

recruiting643%
terminated17%
withdrawn17%
active_not_recruiting17%
completed321%
unknown214%

Recent Activity

7 active trials
Showing 5 of 14
active_not_recruitingearly_phase_1

Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

NCT04544098
recruiting

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

NCT06389097
recruitingphase_1

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

NCT06122610
recruitingphase_1

Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

NCT06663072
recruitingphase_2

177Lu-DOTATATE for Recurrent Meningioma

NCT06326190
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT04544098Early Phase 1

Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

Active Not Recruiting
NCT06389097

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

Recruiting
NCT06122610Phase 1

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

Recruiting
NCT06663072Phase 1

Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

Recruiting
NCT06326190Phase 2

177Lu-DOTATATE for Recurrent Meningioma

Recruiting
NCT01876771Phase 2

A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours

Recruiting
NCT07012330Phase 2

Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients

Terminated
NCT04903899Phase 2

177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma

Recruiting
NCT04385992Phase 2

Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET

Completed
NCT01237457Phase 2

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

Completed
NCT03478358Phase 1

Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors

Unknown
NCT04525638Phase 2

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Unknown
NCT01456078Phase 2

A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors

Completed
NCT01860742Phase 3

Randomized Phase III of PRRT Versus Interferon

Withdrawn

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14